Alerts will be sent to your verified email
Verify Email
HIKAL
|
Hikal
|
Suven Life Sciences
|
Piramal Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Total reactor capacity
|
3459.0 kL | n/a | n/a |
|
R&D as a % of Total Sales
|
4.42 % | 2132.75 % | 0.14 % |
|
Financials
|
|||
|
5 yr Average ROE
|
9.85 % | -82.05 % | 3.82 % |
|
5yr average Equity Multiplier
|
2.2 | 1.55 | 1.94 |
|
5yr Average Asset Turnover Ratio
|
0.77 | 0.05 | 0.55 |
|
5yr Avg Net Profit Margin
|
5.73 % | -1150.51 % | 3.51 % |
|
Price to Book
|
2.63 | 46.36 | 3.41 |
|
P/E
|
52.39 | 0.0 | 282.33 |
|
5yr Avg Cash Conversion Cycle
|
40.84 Days | 97.84 Days | -19.3 Days |
|
Inventory Days
|
60.35 Days | 10.88 Days | 70.13 Days |
|
Days Receivable
|
105.26 Days | 71.91 Days | 77.05 Days |
|
Days Payable
|
105.0 Days | 3.38 Days | 159.9 Days |
|
5yr Average Interest Coverage Ratio
|
4.65 | -373.47 | 2.86 |
|
5yr Avg ROCE
|
12.68 % | -82.34 % | 6.75 % |
|
5yr Avg Operating Profit Margin
|
16.33 % | -1227.3 % | 15.15 % |
|
5 yr average Debt to Equity
|
0.65 | 0.0 | 0.62 |
|
5yr CAGR Net Profit
|
-7.37 % | 17.38 % | -35.79 % |
|
5yr Average Return on Assets
|
4.51 % | -54.63 % | 2.03 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
68.85 % | 70.27 % | 34.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.08 % | 5.29 % | 0.07 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.2 % | 0.0 | 11.78 % |
|
Hikal
|
Suven Life Sciences
|
Piramal Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|